You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The Phase Ib/II trial will assess dosage and antitumor activity of MEN1611 plus Erbitux for patients with PIK3CA-mutated, RAS and RAF wildtype advanced colorectal cancer.
The firms will jointly study the combination, and Sanofi will have an exclusivity period to negotiate the in-licensing of KN026, contingent on certain milestones.
The Phase II DESTINY-CRC01 and DESTINY-Gastric01 underscore the importance of HER2 testing in patients with colorectal cancers and gastric cancers, respectively.
Results of the Phase II monarcHER study suggest that heavily pretreated HER2-positive breast cancer patients may be spared a chemotherapy-based regimen.
In two studies, researchers showed the benefit of combining Tecentriq, Cotellic, and Zelboraf and sticking with continuous versus intermittent dosing of targeted drugs.
Though the Phase II results from the I-SPY 2 trial showed a potential benefit of the regimen in the neoadjuvant setting, additional data are needed.
More than 40 percent of women with advanced mismatch repair-deficient endometrial cancer had an objective response to GSK's anti-PD-1 monoclonal antibody.
Affimed announced the first patient dosed in a Phase I/IIb trial of AFM24, designed to bind CD16A receptors on innate immune cells and EGFR receptors on tumor cells.
The first-in-class VT1021 would treat patients with various cancers whose tumors have high CD36 expression by reprogramming the tumor immune microenvironment.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.